Bugworks Research Inc,[https://bugworksresearch.com/] a global biopharma start-up designing novel broad-spectrum antibiotics, announced the completion of a $7.5M financing, led by University of Tokyo Edge Capital (UTEC)[ https://www.ut-ec.co.jp/english/?utm_source=pr&utm_medium=web&utm_campaign=april] Japan and Global Brain Corporation (Global Brain) Japan [https://globalbrains.com/en/?utm_source=pr&utm_medium=web&utm_campaign=april],a long with Acquipharma Holdings, South-Africa. The company has raised $19M till date and has 3one4 Capital[https://3one4capital.com/?utm_source=pr&utm_medium=web&utm_campaign=apri l] as an existing investor. Logo: https://mma.prnewswire.com/media/1157251/Bugworks_Logo.jpg This investment enables Bugworks to complete Phase 1 studies for its GYROX series Intravenous drug candidate and advance an Oral lead towards clinical development. Bugworks' drug candidate, a dual-target gyrase-topoisomerase inhibitor [https://carb-x.org/portfolio/gallery/], supported by CARB-X [https://carb-x.org/?utm_source=pr&utm_medium=web&utm_campaign=apri] since 2017, is a novel broad-spectrum agent targeting critical bacterial infections implicated in serious hospital, community and biothreat indications. "UTEC led the Bugworks Series A in 2018, as we identified Antimicrobial resistance (AMR) as one of the global issues of mankind, and facilitated Bugworks' collaboration with Japanese ecosystem. Bugworks has thoroughly impressed us with their scientific rigour, pre-clinical data, business development progress and commitment to saving lives. We are now proud to double-down our investment in Bugworks," said Tomotaka Goji, Managing Partner & President, UTEC. "As witnessed with COVID-19, infectious diseases are threatening human existence. AMR is a serious issue and Global Brain regards this as a big unmet medical need. We are proud to partner with Bugworks to bring highly differentiated solutions in AMR to the market. We consider India to be an important region, both from innovation and market perspective and are hence accelerating our investment activity in India," said Yasuhiko Yurimoto, Founder-CEO & General Partner Global Brain. "This new financing is an endorsement of our team and differentiated AMR assets, as we bring reputed global investors to aid our mission of pandemic preparedness by defeating superbug infections," said Dr. Anand Anandkumar, CEO of Bugworks. Investors Profile UTEC is a Tokyo-based early-stage VC with over $500M AUM with 11 successful IPOs and 11 M&As. UTEC invests in seed/early-stage startups that solve global issues of humankind using profound science and technology. Global Brain is a VC firm based in Tokyo with offices in San Francisco, London, Seoul, Singapore and Jakarta. With over $1.5B assets under management, Global Brain has invested in 200+ startups selectively from seed/early to pre-IPO startups and achieved 17 IPOs and 48 M&As. Acquipharma Holdings is a South-Africa based life-science boutique investment fund, who've invested in Bugworks since 2016. Bugworks Company contact: Leela Maitreyi lmaitreyi@bugworksresearch.com www.bugworksresearch.com Source: Bugworks Research Inc.